# Evaxion Halts Infectious Disease and Autoimmune Work to Focus on Cancer Vaccines

Evaxion, a vaccine-focused biotechnology company, has announced it is halting its research and development programs in infectious disease and autoimmune conditions. The company will now concentrate solely on advancing its oncology vaccine pipeline.

The refocusing means Evaxion will prioritize its cancer vaccine candidates, discontinuing work on other therapeutic areas. The decision represents a strategic shift to dedicate all R&D resources to oncology.

**Context**

The move reflects a broader trend in the biotech industry, where companies increasingly concentrate on cancer immunotherapy. Cancer vaccines aim to train the immune system to recognize and attack tumors, a field that has attracted significant investment and scientific interest. By narrowing its focus, Evaxion joins other firms seeking to accelerate development in a competitive but high-potential area of oncology.

Source: [original report](https://www.fiercebiotech.com/biotech/vaccine-biotech-evaxion-progressing-only-oncology-assets-rd-refocus)